Журнал биомедицинских и фармацевтических наук

CD147 Expression as a Prognostic Marker in Patients with Chronic B-cell Lymphoproliferative Disorders

Abstract

Eman Hassanin Bakr, Alaa El-Din Saad Abd El-Hamid, Fadia Mostafa Atia, Ahmed Mostafa Elzaway and Basma Badreldin Hasan

Background: CD147 is expressed at different levels on numerous cell lineages and contains a single highly conserved transmembrane domain containing a glutamic acid that mediates interactions with other transmembrane proteins. CD147 is overexpressed in a broad range of human malignant tumours. CD147 promotes invasive properties, proliferation, and survival of tumour cells. Thus, the overexpression of BSG in tumours is generally regarded as an unfavourable prognostic marker.
Aim: We investigated the expression and prognostic relevance of CD147 in 20 CLL patients vs. 10 DLBCL patients.
Patients and Methods: We examined the 50 individuals (30 NHLs patients, 20 healthy controls) for lymphadenopathy and splenomegaly then, we withdraws peripheral blood samples from the study groups which were analyzed for CBC with blood film, LDH, UA, and immunophenotyping for CD147 on peripheral blood B lymphocytes by FC. Then we reassessed the patient's at 6, 12 month.
Results: At the initial assessment, CD147 positive expression on CD19+ gated population was (26.8 ± 25.7%) compared to the control group with P-value (˂0.05) , these patients also showed associated high LDH, UA, B symptoms, leucocytosis & absolute lymphocytosis. In the reassessment the patients with high CD147 expression the following were observed; fall in the Hb level, PLT count, development of organomegaly, and B symptoms.
Conclusion: High expression of CD147 by immunophenotyping correlates with the patient poor outcome according to international prognostic index (IPI) for lymphoma.